Graham Turner / Alamy Stock Photo
The Medicines and Healthcare products Regulatory Agency (MHRA) has recalled a batch of ramipril 2.5mg capsules after two blister strips of 10mg capsules were found in a pack.
On 28 May 2026, the MHRA published a class two recall notice, while on the same day, Crescent Pharma — the manufacturer of ramipril — said it was recalling the batch.
“Both batches were manufactured at the same site, and the issue appears to have occurred during the secondary packaging process for Batch GR155023,” the recall notice said.
Ramipril is used in the treatment of hypertension, kidney disease and heart failure.
The medicines recall said that healthcare professionals should stop supplying the impacted batch immediately and return affected stock to their supplier.
It advises that if traceability information on the batch is available, healthcare professionals should contact patients and ask them to check the medicines they have been dispensed.
“If batch/product traceability information is not available, pharmacists should identify all patients dispensed this product between 16 Jan 2026 and 22 May 2026. Attempts should be made to contact patients who have been dispensed the impacted product within the last 28 days as a priority,” the recall notice added.
Alison Cave, chief safety officer at the MHRA, said: “If you take Crescent Pharma Limited ramipril 2.5mg capsules, check the packaging for batch number GR155023. The batch number and expiry date information can be found on the outer carton. If you have received this batch, check that the medication strength on the carton matches the blister strips inside.
“If the 2.5mg carton of Crescent Pharma Limited ramipril contains blister strips that are labelled as ramipril 10mg capsules, do not to take the medicine and contact your dispensing pharmacy. If the carton contains blister strips that are correctly labelled as Crescent Pharma Limited ramipril 2.5mg capsules, you do not need to take further action and should continue to take your medicine as usual.”
She added that if a patient believes they have taken 10mg capsules in error and are experiencing side effects, they should seek medical advice.
“Signs and symptoms may include feeling lightheaded, fainting or being fatigued, or altered kidney function and may be more serious for vulnerable patients. Any possible impact of taking a higher dose of ramipril should be assessed by a healthcare professional to determine whether any examination or tests are needed,” Cave said.
Paul Wright, consultant cardiovascular pharmacist at Barts Heart Centre, Barts Health NHS Trust, warned that the recall was important, “given the potential for a four-fold increase in dose”.
“For most patients, however, a limited exposure to the higher dose is unlikely to result in serious harm. As suggested, there may be some clinically relevant effects, such as feeling lightheaded, fainting or being fatigued, or altered kidney function and this may be more serious for vulnerable patients that may require additional investigation. As a large cardiac centre, we are contacting a large volume of patients as part of the recall,” he added.
